Pfizer and BioNTech launch trial of Omicron-targeted Covid vaccine

Pfizer Inc and BioNTech SE said on Tuesday they started a clinical trial to test a new version of their vaccine specifically designed to target the Covid-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen.

Banking on volunteers in the United States, the companies plan to test the immune response generated by the Omicron-based vaccine, both as a three-shot regimen in unvaccinated people and as a booster shot for people who already received two doses of their original vaccine...